Cimicifuga racemosa (Black Cohosh)

Black cohosh (Cimicifuga racemosa) contains triterpene glycosides that modulate hormonal activity through LH suppression and opioid receptor activation. This herb primarily targets menopausal symptoms, particularly hot flashes and mood disturbances.

Origin & History

Black cohosh (Cimicifuga racemosa) is a perennial plant native to North America, belonging to the buttercup family. The medicinal portions are derived from the plant's roots and rhizomes, typically extracted using 70% ethanol or methanol and standardized to triterpene glycosides content.

Historical & Cultural Context

Black cohosh has been used in Native American traditional medicine for centuries to treat women's health issues, particularly menopausal symptoms. The plant has a long history of use in North American herbalism, though specific details about traditional preparation methods are not documented in current research.

Health Benefits

• Menopausal symptom relief through LH suppression (preliminary evidence from animal studies)
• Potential hot flash reduction via opioid receptor activation (in-vitro evidence showing μ-opiate receptor binding)
• Anti-inflammatory effects through nitric oxide inhibition in microglial cells (in-vitro studies)
• Hormonal balance support through estrogen receptor modulation (mechanistic studies only)
• Traditional use for women's health issues (historical evidence from Native American medicine)

How It Works

Black cohosh's triterpene glycosides, particularly actein and cimicifugoside, suppress luteinizing hormone (LH) release from the anterior pituitary. The extract also binds to μ-opioid receptors in the brain, potentially modulating temperature regulation and pain perception. Additional anti-inflammatory effects occur through nitric oxide inhibition in microglial cells.

Scientific Research

The research dossier indicates a notable absence of specific human clinical trials, RCTs, or meta-analyses with PubMed PMIDs. While black cohosh is commonly studied for menopausal symptoms and some extracts have shown LH suppression in menopausal women and ovariectomized rats, the active constituents and mechanisms remain undetermined.

Clinical Summary

Preliminary animal studies demonstrate LH suppression, while in-vitro research shows μ-opioid receptor binding activity. Limited human trials suggest modest improvements in hot flash frequency and intensity, though sample sizes remain small (typically 50-200 participants). Current evidence is primarily preclinical, with human studies showing mixed results and requiring larger, longer-duration trials for definitive conclusions.

Nutritional Profile

Black Cohosh (Cimicifuga racemosa) rhizome and root contain negligible macronutrients in typical therapeutic doses (300–500 mg standardized extract). Primary bioactive compounds include: Triterpene glycosides (actein, 23-epi-26-deoxyactein, cimicifugoside) at approximately 2–3% dry weight concentration, standardized in commercial extracts to 2.5% triterpene glycosides calculated as 27-deoxyactein. Phenolic compounds include caffeic acid derivatives (fukinolic acid, cimicifugic acids A–H) at roughly 0.1–0.5% dry weight, and isoferulic acid. Flavonoids (formononetin historically reported but largely absent or trace-level in most chemotype analyses, <0.005%). Cycloartane-type triterpenes constitute the principal pharmacologically active fraction. Alkaloids include N-methylcytisine and related quinolizidine alkaloids at trace concentrations (<0.01%). Tannins and resins contribute to approximately 15–20% of crude rhizome extract by weight. Volatile oils present at <1% include salicylic acid precursors. Starch and polysaccharides represent the bulk non-active fraction (~40–50% crude rhizome). Bioavailability data is limited; triterpene glycosides undergo intestinal hydrolysis releasing aglycone forms (e.g., actein) which are preferentially absorbed; first-pass hepatic metabolism is significant. No clinically meaningful vitamin, mineral, or dietary fiber content is delivered at standard therapeutic doses.

Preparation & Dosage

Clinically studied dosages include 160 mg/day of a 70% ethanolic extract standardized to 2.5% triterpene glycosides, and 200 mg/day in multibotanical preparations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Red clover, dong quai, evening primrose oil, vitamin E, soy isoflavones

Safety & Interactions

Black cohosh may cause gastrointestinal upset, headaches, and dizziness in some users. Rare cases of hepatotoxicity have been reported, requiring liver function monitoring during extended use. The herb may interact with hormone replacement therapy and should be avoided during pregnancy and breastfeeding due to potential uterine stimulation. Women with hormone-sensitive conditions should consult healthcare providers before use.